Key result
Sirtuin-1 slows vascular calcification by reducing senescence, inflammation, and osteogenic transdifferentiation.
Targeting the Sirtuin-1 pathway with specific activators like resveratrol presents a promising therapeutic strategy for preventing or treating vascular calcification in high-risk patients such as those with chronic kidney disease.
May support Sirt1 activators for vascular calcification in CKD; leaves open whether this alters outcomes in prospective trials.
Vascular calcification (VC) is highly associated with cardiovascular disease and all-cause mortality in patients with chronic kidney disease. Dysregulation of endothelial cells and vascular smooth muscle cells (VSMCs) is related to VC. Sirtuin-1 (Sirt1) deacetylase encompasses a broad range of transcription factors that are linked to an extended lifespan. Sirt1 enhances endothelial NO synthase and upregulates FoxOs to activate its antioxidant properties and delay cell senescence. Sirt1 reverses osteogenic phenotypic transdifferentiation by influencing RUNX2 expression in VSMCs. Low Sirt1 hardly prevents acetylation by p300 and phosphorylation of β-catenin that, following the facilitation of β-catenin translocation, drives osteogenic phenotypic transdifferentiation. Hyperphosphatemia induces VC by osteogenic conversion, apoptosis, and senescence of VSMCs through the Pit-1 cotransporter, which can be retarded by the sirt1 activator resveratrol. Proinflammatory adipocytokines released from dysfunctional perivascular adipose tissue (PVAT) mediate medial calcification and arterial stiffness. Sirt1 ameliorates release of PVAT adipokines and increases adiponectin secretion, which interact with FoxO 1 against oxidative stress and inflammatory arterial insult. Conclusively, Sirt1 decelerates VC by means of influencing endothelial NO bioavailability, senescence of ECs and VSMCs, osteogenic phenotypic transdifferentiation, apoptosis of VSMCs, ECM deposition, and the inflammatory response of PVAT. Factors that aggravate VC include vitamin D deficiency-related macrophage recruitment and further inflammation responses. Supplementation with vitamin D to adequate levels is beneficial in improving PVAT macrophage infiltration and local inflammation, which further prevents VC.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2020) conducted a review in Vascular Calcification. Sirtuin-1 and Sirtuin-1 activators (e.g., resveratrol, vitamin D) was evaluated. Sirtuin-1 decelerates vascular calcification by improving endothelial nitric oxide bioavailability, preventing cellular senescence, and mitigating osteogenic transdifferentiation and inflammation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: